A Double-Blind, Placebo-Controlled Study of Quetiapine and Lithium Monotherapy in Adults in the Acute Phase of Bipolar Depression (EMBOLDEN I)
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The aim of this study was to compare the efficacy and tolerability of quetiapine and lithium monotherapy with that of placebo for a major depressive episode in bipolar disorder. METHOD: 802 patients with DSM-IV-defined bipolar disorder (499 bipolar I, 303 bipolar II) were randomly allocated to quetiapine 300 mg/d (n = 265), quetiapine 600 mg/d (n = 268), lithium 600 to 1800 mg/d (n = 136), or placebo (n = 133) for 8 weeks. Primary endpoint was the change in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The study was conducted from August 2005 to May 2007. RESULTS: Mean MADRS total score change from baseline at week 8 was -15.4 for quetiapine 300 mg/d, -16.1 for quetiapine 600 mg/d, -13.6 for lithium, and -11.8 for placebo (P < .001 for both quetiapine doses, P = .123 for lithium, vs placebo). Quetiapine 600 mg/d was significantly more effective than lithium in improving MADRS total score at week 8 (P = .013). Quetiapine-treated (both doses), but not lithium-treated, patients showed significant improvements (P < .05) in MADRS response and remission rates, Hamilton Depression Rating Scale (HDRS), Clinical Global Impressions-Bipolar-Severity of Illness and -Change, and Hamilton Anxiety Rating Scale (HARS) scores at week 8 versus placebo. Both quetiapine doses were more effective than lithium at week 8 on the HDRS and HARS. The most common adverse events were somnolence, dry mouth, and dizziness with quetiapine (both doses) and nausea with lithium. CONCLUSIONS: Quetiapine (300 or 600 mg/d) was more effective than placebo for the treatment of episodes of acute depression in bipolar disorder. Lithium did not significantly differ from placebo on the main measures of efficacy. Both treatments were generally well tolerated. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00206141.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The latter finding must be reconciled with the fact that quetiapine beat placebo in only three of the five individual trials in patients with BDII, compared to all five in patients with BDI.253, 290, 438, 439, 440”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“orders (see specific disorder sections for evidence), and data show that these agents can significantly reduce anxiety symptoms in patients with bipolar disorder [1409-1413].”
BackgroundMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“…controlled trials report that olanzapine (Tohen et al., 2003c, 2012), quetiapine (Calabrese et al., 2005b; McElroy et al., 2010; Thase, 2006; Young et al., 2010) and lurasidone (Loebel et al., 2014a, 2014b) are effective treatments for bipolar depression, but these studies have significant…”
BackgroundResultInfluentialMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Wolff, A., Joshi, R. K., Ekström, J., Aframian, D., Pedersen, A. M. L., Proctor, G., Narayana, N., Villa, A., Sia, Y. W., Aliko, A., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0153-9 · Cited by 364
McElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., Agambaram, V., Merideth, C., Nordenhem, A., Young, A. H., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04942gre · Cited by 328
“2%).(25) The safety and tolerability profile of quetiapine observed in the current study was generally consistent with that reported in the BOLDER trials.”
MethodResultSelf-citationSajatovic, M., Strejilevich, S. A., Gildengers, A. G., Dols, A., Al Jurdi, R. K., Forester, B. P., Kessing, L. V., Beyer, J., Manes, F., Rej, S., et al. (2015) · Bipolar Disorders · doi:10.1111/bdi.12331 · Cited by 309
Pharmacological treatment of adult bipolar disorder
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0044-2 · Cited by 272
ACOG Committee on Clinical Practice Guidelines–Obstetrics (2023) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000005202 · Cited by 252
Earley, W. R., Burgess, M. V., Khan, B., Rekeda, L., Suppes, T., Tohen, M., & Calabrese, J. R. (2020) · Bipolar Disorders · doi:10.1111/bdi.12852 · Cited by 247
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Won, E., & Kim, Y.-K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122679 · Cited by 223
Durgam, S., Earley, W., Lipschitz, A., Guo, H., Laszlovszky, I., Németh, G., Vieta, E., Calabrese, J. R., & Yatham, L. N. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020164 · Cited by 209
Ostacher, M., Ng-Mak, D., Patel, P., Ntais, D., Schlueter, M., & Loebel, A. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1285050 · Cited by 202
“…Study 1 Thase et al. (2008), Study 2 Lombardo et al. (2012), Study 1 Lombardo et al. (2012), Study 2 Tohen et al. (2003) Tohen et al. (2012) Wang et al. (2014) Calabrese et al. (2005) Li et al. (2014) McElroy et al. (2010) Suppes et al. (2014) Thase et al. (2006) Young et al. (2010) PLO Figure 1.”
ResultSchoeyen, H. K., Kessler, U., Andreassen, O. A., Auestad, B. H., Bergsholm, P., Malt, U. F., Morken, G., Oedegaard, K. J., & Vaaler, A. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111517 · Cited by 197
Weight gain and antipsychotics: a drug safety review
Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.974549 · Cited by 187
Bipolar Disorder — A Focus on Depression
Frye, M. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1000402 · Cited by 170
Lithium: Still a Major Option in the Management of Bipolar Disorder
Licht, R. W. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00260.x · Cited by 168
Earley, W., Burgess, M. V., Rekeda, L., Dickinson, R., Szatmári, B., Németh, G., McIntyre, R. S., Sachs, G. S., & Yatham, L. N. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070824 · Cited by 156
Bipolar Depression: Overview and Commentary
Baldessarini, R. J., Vieta, E., Calabrese, J. R., Tohen, M., & Bowden, C. L. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747955 · Cited by 156
Diagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 205
Fountoulakis, K. N., Tohen, M., & Zarate, C. A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.003 · Cited by 146
A History of the Pharmacological Treatment of Bipolar Disorder
Lopez-Munoz, F. J., Shen, W., D’Ocón, P., Romero, A., & Álamo, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072143 · Cited by 174
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Fountoulakis, K. Ν., Kasper, S. F., Andreassen, O. A., Blier, P., Okasha, A., Severus, E., Versiani, M., Tandon, R., Möller, H., & Vieta, E. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0323-x · Cited by 149
Selle, V., Schalkwijk, S., Vázquez, G., & Baldessarini, R. (2014) · Pharmacopsychiatry · doi:10.1055/s-0033-1363258 · Cited by 128
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Self-citationLithium Treatment Over the Lifespan in Bipolar Disorders
Volkmann, C., Bschor, T., & Köhler, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00377 · Cited by 145
Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f15849 · Cited by 119
Self-citationFindling, R. L., Pathak, S., Earley, W. R., Liu, S., & DelBello, M. P. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0105 · Cited by 118
Fountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Self-citationTherapeutic Drug Monitoring of Common Antipsychotics
Patteet, L., Morrens, M., Maudens, K. E. K., Niemegeers, P., Sabbe, B., & Neels, H. M. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182708ec5 · Cited by 113
Hidalgo-Mazzei, D., Berk, M., Cipriani, A., Cleare, A. J., Florio, A. D., Dietch, D., Geddes, J. R., Goodwin, G. M., Grunze, H., Hayes, J. F., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.257 · Cited by 104
Self-citationTherapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102
De Fruyt, J., Deschepper, E., Audenaert, K., Constant, E., Floris, M., Pitchot, W., Sienaert, P., Souery, D., & Claes, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111408461 · Cited by 95
Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis
Vieta, E., & Valentí, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0073-y · Cited by 106
Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management
Fang, F., Sun, H., Wang, Z., Ren, M., Calabrese, J. R., & Gao, K. (2016) · CNS Drugs · doi:10.1007/s40263-016-0352-5 · Cited by 104
Yatham, L. N., Vieta, E., Goodwin, G. M., Bourin, M., de Bodinat, C., Laredo, J., & Calabrese, J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.147587 · Cited by 79
Kadakia, A., Dembek, C., Heller, V., Singh, R., Uyei, J., Hagi, K., Nosaka, T., & Loebel, A. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03220-3 · Cited by 79
“In the quetiapine trials [36, 37, 40, 41, 43, 47], as few as 50.”
BackgroundDo Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
Pompili, M., Baldessarini, R., Forte, A., Erbuto, D., Serafini, G., Fiorillo, A., Amore, M., & Girardi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101700 · Cited by 78
A review of FDA-approved treatment options in bipolar depression
McIntyre, R. S., Cha, D. S., Kim, R. D., & Mansur, R. B. (2013) · CNS Spectrums · doi:10.1017/s1092852913000746 · Cited by 81
Quetiapine: A Review of its Use in the Management of Bipolar Depression
Sanford, M., & Keating, G. M. (2012) · CNS Drugs · doi:10.2165/11203840-000000000-00000 · Cited by 88
Bauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 75
Self-citationNierenberg, A. A., Sylvia, L. G., Leon, A. C., Reilly-Harrington, N. A., Shesler, L. W., McElroy, S. L., Friedman, E. S., Thase, M. E., Shelton, R. C., Bowden, C. L., et al. (2013) · Clinical Trials · doi:10.1177/1740774513512184 · Cited by 73
Self-citationBerk, M., Daglas, R., Dandash, O., Yücel, M., Henry, L., Hallam, K., Macneil, C., Hasty, M., Pantelis, C., Murphy, B. P., et al. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.186833 · Cited by 69
Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012
Kanba, S., Kato, T., Terao, T., Yamada, K., & Committee for Treatment Guidelines of Mood Disorders, J. S. O. M. D. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12060 · Cited by 68
Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?
Sani, G., Perugi, G., & Tondo, L. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0531-2 · Cited by 76
Malhi, G. S., Gershon, S., & Outhred, T. (2016) · Bipolar Disorders · doi:10.1111/bdi.12455 · Cited by 65
Swartz, H. A., Frank, E., & Cheng, Y. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00988.x · Cited by 63
Lithium for bipolar disorder: a review of the recent literature
Curran, G., & Ravindran, A. V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.947965 · Cited by 68
Managing the side effects associated with commonly used treatments for bipolar depression
Kemp, D. E. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70007-2 · Cited by 62
Machado‐Vieira, R. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.026 · Cited by 75
van der Loos, M. L., Mulder, P., Hartong, E. G., Blom, M. B., Vergouwen, A. C., van Noorden, M. S., Timmermans, M. A., Vieta, E., Nolen, W. A., & for the LamLit Study Group* (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00887.x · Cited by 61
Greil, W., Häberle, A., Haueis, P., Grohmann, R., & Russmann, S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.033 · Cited by 63
Antypa, N., Antonioli, M., & Serretti, A. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.08.005 · Cited by 59
Clinical Pharmacology of Dopamine-Modulating Agents in Tourette’s Syndrome
Mogwitz, S., Buse, J., Ehrlich, S., & Roessner, V. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00010-x · Cited by 60
Zanetti, M. V., Otaduy, M. C. G., SOUSA, R. T. D., Gattaz, W. F., Busatto, G. F., Leite, C. C., & Machado‐Vieira, R. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu058 · Cited by 59
Receptor targets for antidepressant therapy in bipolar disorder: An overview
Fountoulakis, K. Ν., Kelsoe, J. R., & Akiskal, H. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.043 · Cited by 54
Häberle, A., Greil, W., Russmann, S., & Grohmann, R. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-153 · Cited by 57
Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium
Ketter, T. A., Miller, S., Dell’Osso, B. M., & Wang, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.002 · Cited by 62
Toniolo, R. A., Silva, M., Fernandes, F. D. B. F., Amaral, J. A. D. M. S., Dias, R. D. S., & Lafer, B. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1817-5 · Cited by 50
“Remission was defined as a MADRS score of 12 or less, as it has been defined in important published trials in the field (Calabrese et al. 2005; Loebel et al. 2014; McElroy et al. 2010; Young et al. 2010).”
MethodBaghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 57
Self-citationLithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations
Girardi, P., Brugnoli, R., Manfredi, G., & Sani, G. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0139-7 · Cited by 61
Treatment options for acute depression in bipolar disorder
Bauer, M., Ritter, P., Grunze, H., & Pfennig, A. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00991.x · Cited by 49
Self-citationMore good news about the magic ion: lithium may prevent dementia
Young, A. H. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.082875 · Cited by 49
Self-citationPharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
Yalın, N., & Young, A. H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s245166 · Cited by 54
Self-citationPharmacotherapy of Bipolar Disorder with Quetiapine: A Recent Literature Review and an Update
Muneer, A. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.25 · Cited by 54
Young, A. H., McElroy, S. L., Olausson, B., Paulsson, B., (D1447C00001), O. B. O. T. E. I., & Embolden II (D1447C00134) Investigators (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.665177 · Cited by 46
Self-citationApplication of Antipsychotic Drugs in Mood Disorders
RYBAKOWSKI, J. K. (2023) · Brain Sciences · doi:10.3390/brainsci13030414 · Cited by 57
McIntyre, R. S., Durgam, S., Kozauer, S. G., Chen, R., Huo, J., Davis, R. E., & Cutler, A. J. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.12.012 · Cited by 49
Kessing, L. V. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-023-00322-7 · Cited by 63
Refractoriness in Bipolar Disorder: Definitions and Evidence‐Based Treatment
Fountoulakis, K. N. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00259.x · Cited by 44
Cutler, A. J., Datto, C. J., Nordenhem, A., Minkwitz, M. C., Acevedo, L. D., & Darko, D. F. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.002 · Cited by 48
Kemp, D. E., Gao, K., Fein, E. B., Chan, P. K., Conroy, C., Obral, S., Ganocy, S. J., & Calabrese, J. R. (2012) · Bipolar Disorders · doi:10.1111/bdi.12013 · Cited by 39
Sato, H., Ito, C., Hiraoka, K., Tashiro, M., Shibuya, K., Funaki, Y., Yoshikawa, T., Iwata, R., Matsuoka, H., & Yanai, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4002-2 · Cited by 46
Lithium: Current state of the art and future directions
Gitlin, M., & Bauer, M. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-024-00362-7 · Cited by 38
Self-citationAge-Grouped Differences in Adverse Drug Events from Psychotropic Medication
Safer, D. J. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0152 · Cited by 39
Rating Scales in Bipolar Disorder
Sajatovic, M., Chen, P., & Young, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00009-9 · Cited by 57
Efficacy and tolerability of treatments for bipolar depression
Vázquez, G. H., Holtzman, J. N., Tondo, L., & Baldessarini, R. J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.016 · Cited by 42
Mood stabilizers for patients with bipolar disorder: the state of the art
Altamura, A. C., Lietti, L., Dobrea, C., Benatti, B., Arici, C., & Dell’Osso, B. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.181 · Cited by 39
Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges
EPSTEIN, R. A., Moore, K. M., & Bobo, W. V. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s50556 · Cited by 47
Current landscape, unmet needs, and future directions for treatment of bipolar depression
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70005-9 · Cited by 36
Li, H., Gu, N., Zhang, H., Wang, G., Tan, Q., Yang, F., Ning, Y., Zhang, H., Lu, Z., Xu, X., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4215-z · Cited by 40
Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., & Earley, W. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-10 · Cited by 35
“These findings were subsequently confirmed in the similarly designed EMBOLDEN (Efficacy of Monotherapy Seroquel in BipOLarDepressioN) I and II trials (McElroy et al. 2010; Young et al. 2010).”
BackgroundResultInfluentialSelf-citationPotential Utility of Biased GPCR Signaling for Treatment of Psychiatric Disorders
Komatsu, H., Fukuchi, M., & Habata, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133207 · Cited by 41
Bipolar II disorder: a state‐of‐the‐art review
Berk, M., Corrales, A., Trisno, R., Dodd, S., Yatham, L. N., Vieta, E., McIntyre, R. S., Suppes, T. M., & Agustini, B. (2025) · World Psychiatry · doi:10.1002/wps.21300 · Cited by 51
Antipsychotics as antidepressants
Roberts, R. J., Lohano, K., & El‐Mallakh, R. S. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12186 · Cited by 41
McAllister-Williams, H., Sousa, S., Kumar, A., Greco, T., Bunker, M. T., Aaronson, S. T., Conway, C. R., & Rush, A. J. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-020-0178-4 · Cited by 34
Datto, C., Pottorf, W. J., Feeley, L., LaPorte, S., & Liss, C. (2016) · Annals of General Psychiatry · doi:10.1186/s12991-016-0096-0 · Cited by 32
Murasaki, M., Koyama, T., Kanba, S., Takeuchi, M., Shimizu, Y., Arita, E., Kuroishi, K., Takeuchi, M., & Kamei, S. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4977-6 · Cited by 32
Thase, M. E., Bowden, C. L., Nashat, M., Eudicone, J. M., Marcus, R. N., McQuade, R. D., & Carlson, B. X. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2011.632680 · Cited by 32
Mendlewicz, J., Massat, I., Linotte, S., Kasper, S. F., Konstantinidis, A., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., & Souery, D. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833c4ceb · Cited by 34
The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances
Hirschowitz, J., Kolevzon, A., & Garakani, A. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.507042 · Cited by 33
Lithium in the treatment of acute bipolar depression: A systematic review and meta-analysis
Rakofsky, J. J., Lucido, M. J., & Dunlop, B. W. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.058 · Cited by 34
Li, S., Xu, C., Hu, S., & Lai, J. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.25 · Cited by 32
Mood Stabilizers of First and Second Generation
RYBAKOWSKI, J. K. (2023) · Brain Sciences · doi:10.3390/brainsci13050741 · Cited by 37
Carli, M., Weiss, F., Grenno, G., Ponzini, S., Kolachalam, S., Vaglini, F., Viaggi, C., Pardini, C., Tidona, S., Longoni, B., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230224102318 · Cited by 42
Metadata
- Authors
- Young, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators
- Affiliations
- University of British Columbia (CA)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-01-26
- Volume
- 71
- Issue
- 02
- Pages
- 150-162
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2028449820
- Cited by
- 390
- References
- 0
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 18 · 2023: 26 · 2022: 13 · 2021: 38 · 2020: 21 · 2019: 12 · 2018: 21 · 2017: 14 · 2016: 24 · 2015: 24 · 2014: 36 · 2013: 29 · 2012: 33
- FWCI
- 25.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- quetiapine, lithium, bipolar depression, bipolar disorder, atypical antipsychotics, monotherapy, acute depression, antidepressant efficacy, tolerability, sleepiness, nausea, depression remission, dose comparison, bipolar I disorder, bipolar II disorder, anxiety symptoms, mood stabilizers, placebo comparison, Montgomery-Asberg Depression Rating Scale, Hamilton Depression Rating Scale
- MeSH terms
- Quetiapine Fumarate, Adolescent, Adult, Aged, Antidepressive Agents, Bipolar Disorder, Dibenzothiazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome, Lithium Compounds, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.